4-isobutoxy-7H-pyrrolo[2,3-d]pyrimidine | 1309430-79-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 4-isobutoxy-7H-pyrrolo[2,3-d]pyrimidine
• 英文别名: 4-(2-methylpropoxy)-7H-pyrrolo[2,3-d]pyrimidine
• CAS: 1309430-79-2
• 化学式: C₁₀H₁₃N₃O
• 分子量: 191.233
• InChiKey: OJMXXQSLNWZSKJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.178±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-isobutoxy-7H-pyrrolo[2,3-d]pyrimidine 在 N-碘代丁二酰亚胺 、 sodium hydride 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.25h， 生成 5-iodo-4-isobutoxy-7-tosyl-7H-pyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  [EN] 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT
  [FR] COMPOSÉS 4-ALCOXY/ARALCOXY-5-SUBSTITUÉS-PYRROLOPYRIMIDINE EN TANT QU'INHIBITEURS DE TAK1 DANS LE TRAITEMENT D'UNE MALADIE

  摘要：

  公开号：

  WO2014018888A4
• 作为产物：
  描述：

  异丁醇 、 4-氯吡咯并嘧啶 在 18-冠醚-6 、 potassium hydroxide 作用下， 反应 96.0h， 以6.4 g的产率得到4-isobutoxy-7H-pyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  [EN] 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT
  [FR] COMPOSÉS 4-ALCOXY/ARALCOXY-5-SUBSTITUÉS-PYRROLOPYRIMIDINE EN TANT QU'INHIBITEURS DE TAK1 DANS LE TRAITEMENT D'UNE MALADIE

  摘要：

  公开号：

  WO2014018888A4

文献信息

• [EN] COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET MÉTHODES UTILISÉS POUR LA MODULATION DES KINASES ET INDICATIONS À CET EFFET
  申请人：PLEXXIKON INC

  公开号：WO2011063159A1

  公开（公告）日：2011-05-26

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  描述了化合物及其盐、配方、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述化合物或其盐、配方、共轭物、衍生物、形式对至少一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述化合物在抑制Ras突变细胞系增殖方面具有活性。还描述了使用这些方法来治疗疾病和病况，包括与B-Raf V600E突变蛋白激酶活性相关的疾病和病况，包括黑色素瘤、胶质瘤、胶质母细胞瘤、乳头状星形细胞瘤、结直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠间质瘤、胆道癌和胆管癌。还描述了使用这些方法来治疗与c-Raf-1蛋白激酶活性相关的疾病和病况，包括急性疼痛、慢性疼痛或多囊肾病。
• Compounds and Methods for Kinase Modulation, and Indications Therefor
  申请人：Ibrahim Prabha N.

  公开号：US20110152258A1

  公开（公告）日：2011-06-23

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  本文描述了化合物及其盐、制剂、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述的化合物或其盐、制剂、共轭物、衍生物、形式对至少一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述的化合物对抑制Ras突变细胞系的增殖具有活性。还描述了使用这些化合物的方法来治疗与B-Raf V600E突变蛋白激酶活性相关的疾病和病症，包括黑色素瘤、胶质瘤、多形性胶质母细胞瘤、毛细胞星形胶质瘤、结肠直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠间质瘤、胆道癌和胆管癌。还描述了使用这些化合物的方法来治疗与c-Raf-1蛋白激酶活性相关的疾病和病症，包括急性疼痛、慢性疼痛或多囊肾病。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20140288070A1

  公开（公告）日：2014-09-25

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  本文描述了化合物及其盐、制剂、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述的化合物或其盐、制剂、共轭物、衍生物、形式至少对一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述的化合物具有抑制Ras突变细胞系增殖的活性。还描述了使用它们治疗疾病和病症的方法，包括与B-Raf V600E突变蛋白激酶活性相关的疾病和病症，包括黑色素瘤、胶质瘤、多形性胶质母细胞瘤、毛细胞星形细胞瘤、结直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠道间质瘤、胆道癌和胆管癌。还描述了使用它们治疗与c-Raf-1蛋白激酶活性相关的疾病和病症的方法，包括急性疼痛、慢性疼痛或多囊肾病。
• 4-ALKOXY/ARALKOXY-5-SUBSTITUTED-PYRROLOPYRIMIDINE COMPOUNDS AS TAK1 INHIBITORS IN DISEASE TREATMENT
  申请人：Confluence Life Sciences Inc.

  公开号：US20150203499A1

  公开（公告）日：2015-07-23

  The present disclosure provides 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds, pharmaceutically acceptable salts, solvates and pharmaceutical compositions of compounds embraced by Formula (I), providing a therapeutic benefit to subjects with disease conditions, especially cancer, wherein R 1 and R 2 are as defined in the detailed description.

  本公开提供4-烷氧基/芳氧基-5-取代-吡咯蒽嘧啶化合物、药学上可接受的盐、溶剂和由式(I)所包含的化合物组成的制药组合物，为患有疾病情况的受试者提供治疗益处，特别是癌症，其中R1和R2如详细说明中所定义。
• N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
  申请人：Plexxikon Inc.

  公开号：EP2501236B1

  公开（公告）日：2017-03-29